Our Team
Prof Cather Simpson
Professor Cather Simpson is one of New Zealand's shining stars for commercialisation and is passionate about inspiring researchers to understand the opportunities that stem from commercialising deep tech as a career path. Cather joined Pacific Channel as a partner in 2021 to assist in identifying and advancing potential commercialisation projects which meet Pacific Channel's criteria for investment. Cather is a professor at the University of Auckland, a joint appointment between the physics and chemistry departments and co-founder of the Photon Factory laser lab, Engender and Orbis Diagnostics.
Paul Muckleston
Paul Muckleston joins Pacific Channel as a Venture Partner.
Previously, Paul was the Chief Operating Officer for Microsoft’s world-wide Public Sector business. Paul enjoyed a successful and diverse career at Microsoft in various leadership roles based in New Zealand, France, Germany and the United States, travelling professionally to 70+ countries.
Paul brings hands-on experience in developed and developing markets, start-ups and mature organizations, governance, strategy development, organization transformation and people leadership. He has deep expertise in revenue accountability, channel strategy, go-to-market models and global operations leadership.
Paul knows firsthand how to scale businesses globally having been on senior leadership teams across Europe and Asia and for 6 years in Seattle based global leadership roles. These global roles had responsibility across 100+ countries, direct teams of >250 FTEs, indirect orgs of >3,000 FTEs and revenues from <$60M growth businesses to >$20B mature operations. Paul’s developed a keen sense for balancing the differences in country culture, size and scale with consistent performance and execution accountabilities.
Cherie Tirikatane-Le Cheminant
Ngāi Tahu
From connecting and coordinating Māori-led enterprises through to enabling communities to deal with the social, economic and environmental challenges they face, Cherie’s work is centered around helping people become more self-determining.
She is a passionate advocate for hapū, whānau and marae-based development and leads and advises on a multitude of projects that aim to advance economic growth and environmental sustainability, not just for Māori and Pacifica but for everyone in Aotearoa.
Cherie is the CEO of SEED NZ and the founder of Whānau Power, a project aimed to solve Energy Hardship. She is the founder of He Pito Mata Ltd. and has been involved in Māori Media Sector Shift, an initiative to support the revitalisation of te reo Māori and greater awareness and understanding of Māori stories and workforce development within the Māori Media Sector.
Previously, she was COO for Ekos, an international non-profit enterprise focused on sustainable reforestation and carbon farming, CEO of BIZview, and GM of Pentech Communications Ltd.
The community development programs that Cherie has founded, are all designed to help communities improve their quality of life. She is most passionate about helping people realise their potential, and to collectively create tangible solutions and results.
Her kaupapa is widely supported, as she continues her efforts to ensure that everyone in Aotearoa has access to the resources they need so they can grow and help future generations thrive.
Mohan Nair
CEO Emerge® Inc
Mohan is a corporate innovation culture enthusiast but pragmatic enough to know that not all things you dream can be real.
Through numerous business transformation experiences, Mohan has designed and implemented corporate machinery and culture to launch new ideas from either, a corporate chassis or on its own, utilising cause-centered transformation.
Born and raised in Singapore, with firsthand experience of how nations transform, Mohan’s experiences in the USA have shaped how he strives to create lasting business transformation.
As an Edmund Hillary Fellow, Mohan is assisting New Zealand in transforming.
As a former TV talk show host, musician, and the first healthcare executive to audition and lose at America’s Got Talent, Mohan hopes to inspire and teach all things transformational.
Marny Reakes
Marny brings 30 years of operational and business experience in heavy industry and the extraction of critical minerals. After several decades of working internationally, Marny is returning to New Zealand to help cultivate and scale deep tech engineering and science-based innovations that have the potential to solve some of our most complex environmental challenges, aligning with our focus on investing in our future.
Kieran Jina
Kieran joined Pacific Channel in 2015 and manages the investment process and post-investment support. His approach is to ensure that R&D, product development, IP and business development strategies align with market needs, competitive whitespace and liquidity strategy. Kieran takes an active role in guiding the formation, investment, development and commercialisation of technologies and companies, and empowering their teams.
Kieran has held a range of operational, management and governance roles across medical devices, diagnostics, therapeutics, agritech and clean-tech companies. He is currently seconded part-time as CEO of Upstream Medical Technologies, which is developing novel biomarkers to increase the efficiency of chest pain triage within emergency departments. In addition to directorships of companies within PacificChannel's portfolio, he sits on the Executive Council for BiotechNZ and is a member of the Return on Science investment committee for Medtech & Surgery.
Kieran commenced his career at the now ASX-listed device company, Aroa Biosurgery. Subsequently, he became Chief Operating Officer of Engender Technologies, which was developing a novel cytometry system for sorting bull semen by sex chromosome content. He led its product development planning and drove the process for the company to be strategically acquired.
Kieran holds degrees in Master of Science (Hons) and Master of Bioscience Enterprise (Hons).
Brent Ogilvie
Brent Ogilvie is a co-founder and Managing Partner of Pacific Channel.
Mr Ogilvie was also previously the founding investor director of Engender Technologies, which developed a proprietary process to separate X (female) and Y (male) bearing bull sperm cells to enable cattle farmers to choose the sex of offspring. Mr Ogilvie co-founded Engender and led it from foundation to its successful sale to a global dairy genetics company generating a significant capital return for its scientists, Auckland UniServices, Pacific Channel and its co-investors.
Mr. Ogilvie was co-founder, founding CEO and Director of Somnaceutics, which developed asleep enhancement tonic, which was sold to New Image Group: Mr. Ogilvie was also Director of Ecodiesel, a biodiesel technology company that sold its business assets to Z Energy.
Mr. Ogilvie was previously New Zealand Consul and Trade Commissioner to New York. He holds a BSc (Biological Sciences) from the University of Waikato and an MBA from The University of Auckland.
Lifei Wang
Lifei Wang joined Pacific Channel in 2017 as part of the Greater China Team. Lifei is involved in marketing and attracting investment, acquirers, and strategic parties from the Greater China region to our portfolio companies. Lifei has connections with Chinese media outlets, which allow for publicity of Pacific Channel and our portfolio.
Lifei has extensive experience in marketing, with aNew Zealand Level 7 Diploma in Business & Marketing.
While working in China, Lifei gained extensive experience in journalism and developing marketing campaigns for a large local news outlet in Beijing.
Bronwynne Howse
Bronwynne works with Pacific Channel through her communications consultancy, Joyce & Howse Consulting. Throughout her career, she has advised and supported a diverse range of companies from scaling start-ups, SME's to large multi-national organisations across different industries.
Richard Pinfold
Richard joined Pacific Channel in November 2022, having returned to New Zealand after working in Europe. He has previous experience working alongside Pacific Channel during his time with the MacDiarmid Institute and Dodd Walls Centre where he looked after commercialisation projects for these Centres of Research Excellence.
While in Europe, Richard worked for a private equity firm with a focus on wind and solar ventures.
Richard has a BA and BCom from Auckland University and an International Certificate in Wealth Management from The Chartered Institute for Securities and Investment.
Dr Ashwath Sundaresan
Dr Ashwath Sundaresan leads Pacific Channel’s investments into cleantech/ advanced engineering opportunities and supports work in medical devices. Ashwath joined Pacific Channel in July 2021 and has over 10 years' experience across technology and deep IP based business.
Immediately before to joining Pacific Channel, Ashwath spent three years as a Senior Commercialisation Manager at Wellington UniVentures (the commercialisation company of Victoria University of Wellington) focussing on developing academic entrepreneurs and university spinouts. Prior to that, Ashwath was a strategy and technology advisor with Accenture and Google with significant expertise in the healthcare and energy industry.
Ashwath is passionate about early-stage deep technologies and businesses and is also a director of Vortex Power Systems (a Pacific Channel portfolio company). Ashwath holds a Bachelor of Mechanical Engineering and PhD in mechanical engineering from University of Canterbury and an MBA from INSEAD.
Dr Sheryl Tan
Sheryl joined Pacific Channel in January 2024 as an associate in the investment team. Sheryl’s primary role will be to assist in undertaking due diligence of potential investments, specifically R&D and scientific reviews and work with our portfolio companies as they develop their products.
Before joining Pacific Channel, Sheryl was a Research Fellow at the University of Auckland, where she conducted foundational, anatomical studies of the human spinal cord and was a departmental advisor for the Masters of Science/BiomedicalScience programme, overseeing project progression, completion and pastoral care.
Sheryl first became interested in venture capital after being approached by our portfolio company, Kitea Health to help develop their pressure-sensing device in brain tissue, a project that aligned with Sheryl’s values and the reason why she pursued a career in science.
In her spare time, Sheryl is a selector and technical officer for Weightlifting New Zealand and has recently taken on a new challenge, joining the sailing crew of a Young 88.
Sheryl has a Doctor of Philosophy and a Bachelor of Science with first-class honours.
Georgia Houghton
As Executive Assistant to the Director and Managing Partner of Pacific Channel, Georgia’s supportive role stretches from investor relations to operations and marketing. She maintains and refines internal processes that support management, coordinating internal and external resources to expedite workflow and ensure company objectives are met.
Georgia holds a B.S. in Business Administration with emphases in Management and Public Relations from the Master’s University, California.
Dr Roland Toder
Dr Roland Toder has extensive life sciences and international business development expertise. He has previously worked as a manager, board member and consultant to numerous successful companies in NZ and in Europe. Roland brings a wealth of knowledge to Pacific Channel and helps the team with technical due diligence, scientific validation, valuation of early-stage startups, technology transfer, international licensing as well as advising on the commercial arrangements of our portfolio companies.
Roland resides in Golden Bay, NZ and holds dual Citizenship in Germany & New Zealand.
Emily Moore
Emily works with Pacific Channel through her legal practice, De Novo Legal, providing part-time in-house support on day to day matters. She has spent most of her career working as a senior in-house lawyer, recently holding General Counsel and Head of Legal positions leading legal teams in Sydney.
Emily has worked in and with a range of New Zealand and Australian businesses and industries, from multi-national IT and telecommunications companies through to SMEs and scaling start-ups.
Dr Robert Powell
Dr Robert Powell has 15 years’ experience identifying opportunities, forming and nurturing deep-tech ventures.
A former academic (PhD, Biochemistry, University of Otago), Robert worked on the academic side of the commercialisation process managing the commercialisation program for a US biotechnology focused research University.
For the last decade he has worked for investors (Angel and VC) in the US and NZ, while managing a deep-tech due diligence consultancy. He returned to NZ eight years ago after two decades in the US and has been working with Pacific Channel since 2018. Robert brings broad experience having worked with medical, human, animal and aquatic technologies and start-ups. He has experience in forming, financing, operating and staffing deep-tech ventures.
Dr Gary Pace
Dr Gary Pace is an experienced serial entrepreneur, director and senior operations manager of small to large-scale life sciences ventures inAustralia, New Zealand and the USA. He has more than 40 years of experience in the development and commercialization of advanced technologies including in the biotechnology, pharmaceuticals, medical devices and food industries.
Dr Pace currently serves as a Director of Pacira Pharmaceuticals Inc (NASDAQ:PCRX), Cardiff Oncology (NASDAQ: CRDF), Simavita Ltd (ASX: SVA) and AntisenseTherapeutics (ASX: ANP) as well as several private companies.
He also served as a director of ResMed Inc (NYSE: RMD) from its inception in 1994until 2018. Gary was instrumental in the growth of the company to a market capitalization of US$28bn.
In New Zealand, he is Executive Chairman of Pacific Channel portfolio company InsituGen, which is developing tests to detect performance enhancing drugs in racehorses and humans. Also, he is a director of Upstream Medical Technologies, which is developing biomarker-based tests for rapid and accurate front-line diagnoses of heart disease and associated clinical complications.
He has also previously served as a director of two Pacific Channel portfolio companies that have since been acquired; Somnaceutics and Engender Technologies.
Dr Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D.from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. He has authored or co-authored over 50 research and review papers as well as 24 patents. He has held visiting academic positions at the Massachusetts Institute of Technology and the University of Queensland. Dr.Pace is an elected Fellow of the Australian Academy of Technological Sciences and Engineering. In 2003 he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was named 2011 Director of the Year (corporate governance) by the San Diego Directors Forum.
Dr Pace was born in Sydney Australia and holds both US and Australian citizenship. He lives in La Jolla, California,USA.
Robert McPhail
Robert McPhail joined our team as an Investment Analyst in 2019.
Robert’s primary role is to provide support to management with capital raising activities, deal-structuring and syndications with co-investors where Pacific Channel is the lead investor or an existing shareholder.
His entrepreneurial flair assists our portfolio companies with business development advisory work particular around corporate growth strategy.
Robert has a passion for technology companies, particularly ones that can have significant global impact. Outside of work Robert enjoys golf and socializing with his friends and family.
Louis Newton
Louis Newton joined the Pacific Channel team in 2023 as an associate.
His primary role is to provide support to the investment team as they analyse and assess potential investments, undertake due diligence, and develop commercialisation strategies. Louis's skills and experience in building business dashboards that underpin data-driven decision-making will assist our science and engineering-based portfolio companies to constantly test key hypotheses and quickly adapt their technology design and business strategies.
Louis has a BSC in physics, chemistry and maths and a BA in philosophy from the University of Auckland.
Outside of Pacific Channel, Louis produces electronic and ambient music and he’s currently developing an open-source board game. He’s also passionate about cooking and spent a year working as a sous-chef in Melbourne.
Joe Victor
Joe Victor currently serves as President & CEO of RareCyte, a precision biology company providing instruments, consumables, and services to academic medical centers and biopharma companies based in Seattle, WA, USA.
Mr. Victor has also been a Venture Partner/Venture Advisor with 5AM Ventures since 2016. Prior to joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences (5AM Ventures portfolio company), CEO of DVS Sciences (acquired by Fluidigm Inc.) and Applied Precision Inc (acquired by GE Healthcare). He currently serves on the Boards of RareCyte, and Magnetic Insight. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Mr. Victor previously held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.
Advisors
John Hackett
A career of 45 years as an Intellectual Property Lawyer and Patent Attorney, specialising particularly in all areas of trademark law from brand creation through to litigating the enforcement of IP rights.
Partner at both AJ Park and Baldwins IP over a period of 35 years.
Chairman at AJ Park for 7 years between 2013 and 2019.
Acted for many overseas corporates, including Disney, Warner Bros, Lacoste, Citibank, Ferrari, L’Oréal and BIC.
New Zealand companies included Mainfreight, Farmers, Healtheries, Navman and Manuka Health, as well as a large number of New Zealand wine companies and start-ups in association with The Icehouse.
In 2016 won the Who’s Who Legal award for International Trademark Lawyer of the Year.
A Notary Public and served on the Council of the New Zealand Society of Notaries for 6 years.
Currently, a Brand Ambassador for New Zealand legal software developer, Sortify.tm Limited, a locally based legal tech start-up.
Sam Knowles
Sam has spent the last decade in governance roles supporting young and ambitious growth companies. Examples include Xero in accounting software, Magritek in scientific instruments, PartnersLife in insurance and Synlait in the food/dairy industry.
During the prior decade, Sam was the founding CEO of Kiwibank, leading it from idea to success. This role followed an extensive career in financial services with senior executive roles in Australia and New Zealand.
Sam has a BSc in Physics from Waikato University and an MSc (Hons) in Resource Management from Canterbury University.
Dr Allan Goldberg
Dr Allan Goldberg is a biotechnology entrepreneur, and has been a CEO, Board member, and advisor for both private and public companies with marketed and R&D stage products. He has been involved primarily in therapeutics companies focused either on oncology or infectious disease. Currently, he is on the board of New Zealand-based Orbis Diagnostics, a company developing a rapid, quantitative, low-cost, portable point-of-care diagnostic platform technology that will be used initially to detect neutralizing antibodies after SARS-CoV-2infection, but that also has broad applicability for detection of other infectious agents. Dr Goldberg is currently the CEO of DetectOn Diagnostics,Inc., a US-based company focused on early detection of cancer.
Prior to entering the biotech industry, he was a professor of virology at The Rockefeller University, where his lab focused on viral oncology. Allan holds a B.A. from Cornell University and a Ph.D. in Biochemistry/Biology from Princeton University.
Colin Dawson
Colin chairs the Boards of The Environmental Protection Authority, Upstream Medical Technologies, Manaaki Whenua Landcare Research, Tiro Medical and Ember Wellbeing Trust. He is also a member of the Boards of MARS Bioimaging, and the NZ Institute for Plant and Food Research.
Following 10 years in veterinary clinical practice Colin held a number of senior executive positions in the primary,secondary and tertiary health care sectors. Executive roles have included GM Clinical Support at Waikato DHB, CEO of Integrated Care IT company, HSA Global, CEO of Otago Innovation, the commercialisation arm of the University of Otago and Executive Director- Group Strategy of healthcare REIT The Calan Group.
Colin was a founding partner in health consulting and investment banking services firm Medicus Capital. Colin is a former director of the NZX-listed companies BLIS Technologies and Pacific Edge, and former Trustee of the Upstart Business Incubator. He is a Past President of The Dunedin Club, a Chartered Fellow of the NZ Institute of Directors and an SEP alumnus of the Stanford University Graduate School of Business. A graduate of the University of Auckland's Business School, Colin serves on the University's Return on Science Agritech, Medtech. and Surgical Investment Committees. His interests are the commercialisation of Intellectual Property and the effective governance of technology-based businesses and companies where disruptive technology is bringing change to the existing competitive landscape.
Bridgit Hawkins
From my earliest days of helping on the family farm to founding a technology business focused on enabling financial and environmental sustainability for farmers, I am passionate about making a difference in the agricultural sector. Since the successful exit of Regen to CropX in 2020 I have continued to be involved with Regen and CropX, taking up a role of chief Sustainability Officer for CropX. The broad experience I have gained over my career enables me to bring together knowledge and expertise from business, technology, science and social science to develop solutions today for tomorrow's challenges.
Dr Selwyn Yorke
Selwyn Yorke is a biotech consultant, a Director who holds two Chair and three Board positions on deep tech start-up organisations. He has several Advisory roles and enjoys being a business mentor (BMNZ). To support environmental recovery, Selwyn Chairs a community-based native tree planting and environmental management group. He is an Impact Advisor to groups at two Research Institutions.
Selwyn is an Investment Committee member of the Manawatu Investment Group Fund 3 in which he assesses many types of start-up companies, including foodtech, biotech, agritech and SaaS businesses for investment opportunities. Furthermore, he is a member of the Return on Science Manawatu Momentum committee and recently became a Chiasma Manawatu mentor.
Selwyn has a career of project management related activities including drug development, medical devices, natural products and related technology, including early-stage manufacturing.
Selwyn was Business Development Manager at New Zealand Pharmaceuticals Ltd (NZP), a GMP certified manufacturer of drug substances, pharmaceutical intermediates and natural products. He contributed to global sales of a range of NZP products and retired from NZP in June, 2016.
Selwyn is a graduate of the University of Canterbury (PhD chemistry) and in the post-grad period, he worked in academia for several years, in a tech start-up and at the Chemistry Division, DSIR.
Roger Hatrick Smith
Roger’s domestic and international business advisory experience spans 40 years. He has a deep understanding of the issues and challenges facing businesses wanting to grow both in New Zealand and offshore. He has advised many businesses through various stages of growth offering insights and knowledge acquired through many years of working closely with entrepreneurs and their businesses. As a 10+year partner at EY, Roger initially was a partner in EY consulting and after the sale of their consulting practice to Cap Gemini headed the Australasian public sector consulting practice for four years. Subsequently Roger was partner in charge of the Entrepreneurial Services and Transaction Advisory service lines at EY and was a member of the executive management group of the Firm.
Roger is a founding Director of VCFO Group Ltd after forming the original VCFO Firm in 2007 and is responsible for the accounting and business advisory areas of the Firm. He has experience across a number of business areas including commercial property management, property development and a range of young entrepreneurial start-up companies and provides advice on guidance on growth; access to capital; strategy commercialisation; valuations; and acquisitions and divestments.
Roger is a Chartered Accountant and has postgraduate management qualifications from Massey University.
Blair Pritchard
Blair Pritchard was previously a Partner at Pacific Channel but is still involved in an advisory capacity. He is now based in Sydney, where he is a director of the Clean Energy Finance Corporation (CEFC). At the CEFC, he is responsible for increasing the innovative and early stage investing activities. This includes pioneering new investment programs designed to promote clean energy innovation, investing directly in early stage companies, and advising such companies on growth strategies.
Blair was the Chief Investment Officer of My Angel Investment, an equity crowdfunding platform as well as the CFO of Phoenix Water, a Melbourne based water technology company
Blair has also worked at Macquarie, where he ran a team making principal investments in early stage clean-tech and environmental companies as part of the Macquarie Group. This role included setting up/acquiring early stage companies and remaining actively involved in their ongoing management including Board representation. The business reached profitability after two years.
Prior to that he acted as Chief Investment Officer of a $7bn funds management unit within Macquarie. Earlier in his career, Blair worked as an investment analyst for Mercer Investment Consulting, performing asset-liability modelling for Australian pension funds.
Blair’s areas of interest include financial structuring and product development cycles in early stage companies. He has law and economics degrees from Victoria University of Wellington and is a graduate of the Australian Institute of Company Directors.
Dr Hans Albrecht
Hans is a founding member Chairman of Global Bridges, a Berlin based German NGO that aims to foster better understanding between opinion leaders in politics, business, science and the media in Germany and a number of other countries such as China, Russia, Iran, Israel and Palestine and several other countries in Eastern Europe, Asia and Africa.
In his commercial life, Hans Albrecht is a Managing Partner and founder of Nordwind Capital, a Munich based private equity investor.
Prior to founding Nordwind Dr. Albrecht was managing director and co-founder of Carlyle Europe Partners, the European arm of the Washington based Carlyle Group and before that he was managing director and partner of IMM Industries Management, one of the leading German private equity companies at that time.
He started his career as a consultant with The Boston Consulting Group in Munich.
Hans holds a Ph.D. in medicine, the equivalent of an LL.B. from the University of Würzburg, an L.L.M. from the Harvard Law School and an M.B.A. from INSEAD. He is a Fulbright scholar and is registered as an attorney with the New York Bar.
Hans is a member of the Foundation Council of the Munich Security Conference and as a private investor he is amongst other activities a member of CargoBeamer AG’s supervisory board and the spokesman of the CargoBeamer investor group.
Dr Sunil Vather
Sunil believes a thoughtful business plan underpins a platform of common understanding between all interested parties in a venture. This enables the establishment of shared goals and improved teamwork between technologists, the staff, and business partners. In particular, he works towards converting complex science and business concepts into simple and understandable language.
Sunil has over 30 years’ experience in transforming innovation into business success. His first commercial project in 1987 saved his employer $3 million per annum and helped introduce an enhanced product range. After emigrating to New Zealand in 1993, he managed the intellectual property portfolio of 120 patents for Industrial Research Limited (now Callaghan Innovation). He sold and licensed the intellectual property in New Zealand, Australia, Japan and the USA.
In 2000 he was appointed General Manager of Science at Industrial Research Limited with 250 direct reports and a budget of $30 million. In 2005 he was appointed CEO of the Building Research Association and in 2008 he began his own entrepreneurial activity. In recent years he has assisted over 20 innovative concepts to progress to start-up companies or commercialization.
Sunil has held numerous governance positions including at MacDiarmid Institute for Advanced Materials and Nanotechnology, International Council for Research and Innovation in Building and Construction (CIB) and Damping Systems Limited (joint venture with Oiles Corporation, Japan). He currently holds positions in Edpotential Ltd, Westmedic Ltd, Ablex Ltd and is an advisor to Toku Eyes Ltd and Cetogenix Ltd.
Sunil holds a doctorate degree from the University of Oxford (UK, on scholarship), MBA from University of Witwatersrand (South Africa, on scholarship) and has received executive training from the Darden Business School (USA).
Professor David Williams
David is an internationally award-winning scientist and recognized global expert in immunoassay development, electrochemistry and chemical sensors. He was formerly Head of Chemistry at University College London and Chief Scientist at Alere (when known as Inverness Medical Innovations) at the time when it developed Clearblue Digital, the first digital home pregnancy test. David co-founded Capteur Sensors Ltd and Aeroqual Ltd. He is currently based at The University of Auckland and is an Emeritus Investigator of the MacDiarmid Institute for Advanced Materials and Nanotechnology, and Associate Investigator of the Maurice Wilkins Centre for Biodiscovery and of the Centre for Medical Device Technology. He is an Adjunct Professor at the University of Queensland.
